Understanding How the Oral Weight Loss Medicine MK-4082 Is Processed Alone and With Diltiazem in Healthy Adults

What this Trial Is About

Researchers are studying a new oral medicine called MK-4082, designed for weight loss in people with higher body weight. This trial focuses on healthy adults to understand how MK-4082 behaves in the body over time. The study also compares MK-4082 levels when taken alone and when combined with another medicine called diltiazem, while checking safety and tolerance. Participants go through two parts in this study. In Part 1, they receive a single oral dose of MK-4082 alone, then a single oral dose of MK-4082 combined with multiple doses of diltiazem. In Part 2, participants receive either a single dose of MK-4082 or a placebo. Ondansetron is provided as a rescue medication to help prevent nausea or vomiting. During the study, participants are monitored for drug levels in their blood at specific times up to about one week after dosing. Researchers also track any adverse events, including whether participants stop treatment due to side effects. The study measures include maximum drug concentration and how long the drug stays in the body. Overall participation lasts several weeks, with assessments during and after dosing to ensure safety and collect data.

A Clinical Trial of MK-4082 in Healthy Participants (MK-4082-005)